News
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Successful 2024 Annual General Meeting of SCHOTT Pharma: Shareholders approve all items on the agenda
SCHOTT Pharma's 2024 AGM sees shareholders approving all agenda items. The company continues on its profitable growth path, focusing on high-value solutions for pharmaceutical trends -
-
-
-
COMMUNIQUÉ DE PRESSE
SCHOTT Pharma delivers on 2023 targets and continues profitable growth trajectory
SCHOTT Pharma AG & Co. KGaA delivers on 2023 targets with 9% revenue growth to EUR 899m and maintains high EBITDA margin of 26.6%. Strategic shift towards high-value solutions accelerates with strong profitability.